Summary
Other Scenarios:
- TM - GSK
- TM - PEP
- GSK - PG
- PEP - PG
| Buyer: | Toyota Motor Corporation (ADR) (TM) | Last Price: | 122.91 | Market Cap.: | 196.53B |
|---|---|---|---|---|---|
| Target: | The Procter & Gamble Company (PG) | Last Price: | 62.15 | Market Cap.: | 195.71B |
Lines of Business Summary:
- Toyota Motor Corporation (ADR) (TM) competes in 2 industries and 3 product/service groups
- The Procter & Gamble Company (PG) competes in 3 industries and 55 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Toyota Motor Corporation (ADR) (TM) has 5 and The Procter & Gamble Company (PG) has 10 suppliers that rely on a material % of their business. They share 0 in common.
- Toyota Motor Corporation (ADR) (TM) has 0 and The Procter & Gamble Company (PG) has 1 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Finance |
|
1,298 | |
|
*Healthcare |
|
925 | |
|
*Media |
|
146 | |
|
Manufacturing |
|
|
1,189 |
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 6)
|
Target (Total: 75)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 86)
|
Target (Total: 63)
|
Buyer (Total: 9)
|
Target (Total: 10)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 299,394 | 138,000 |
| Revenue Per Employee | 699,518.9 | 543,343.7 |
| Total Revenue | 51,424.8 | 18,694.0 |
| Total Expenses | 46,790.0 | 15,048.0 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
41,154.3 | 9,057.0 |
|
SG&A Expense
|
5,635.7 | 5,991.0 |
|
Research & Development
|
0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
4,634.8 | 3,646.0 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
34.61 | 24.23 |
|
Fwd P/E
|
13.44 | 20.66 |
|
Fwd P/Rev
|
0.93 | 2.59 |
| Book Value | 96,161.9 | 65,053.0 |
|
Curr Portion of LTD/Cap Lease
|
19,239.7 | 12,168.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Manufacturing > Industrial Manufacturing > Transportation Equipment > Consumer Vehicles > Cars
Target
Focused ():
Manufacturing > Consumer Manufacturing > Personal Care and Cleaning Products
Business Description
Buyer
Toyota Motor Corporation (Toyota) primarily conducts business in the automotive industry. Toyota also conducts business in the finance and other industries. Its business segments are automotive operations, financial services operations and all other operations. Its automotive operations include the design, manufacture, assembly and sale of passenger cars, minivans and trucks and related parts and accessories. Toyota's financial services business consists primarily of providing financing to dealers and their customers for the purchase or lease of Toyota vehicles. Its financial services also provide retail leasing through the purchase of lease contracts originated by Toyota dealers. Related to Toyota's automotive operations is its development of intelligent transport systems . Toyota sells its vehicles in more than 170 countries and regions. Toyota?s primary markets for its automobiles are Japan, North America, Europe and Asia.
Target
The Procter & Gamble Company (P&G) is focused on providing branded consumer goods products. The Company is organized into three global business units: Beauty and Health; Household Care, and Gillette GBU. Its products are sold in over 180 countries around the world primarily through mass merchandisers, grocery stores, membership club stores and drug stores. The Company owns or has licenses under patents and registered trademarks, which are used in connection with its activity in all businesses. Some of these patents or licenses cover product formulation and processes used to manufacture its products. P&G created new categories with new brands, such as Febreze, Swiffer, Kandoo, Prilosec OTC and ThermaCare. In September 2006, the Company's Sure brand (an antiperspirant and deodorant brand) was acquired by Innovative Brands, LLC. In January 2007, P&G acquired HDS Cosmetics Lab Inc., which manufactures and markets Doctor's Dermatologic Formula (DDF) skin care.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
19.71 | 51.89 |
|
Operating Margin %
|
9.35 | 19.99 |
|
Quick Ratio
|
0.76 | 0.36 |
|
Current Ratio
|
1 | 0.73 |
|
Coverage Ratio
|
0.05 | -0.09 |
| Total Assets | 264,652.7 | 135,695.0 |
| Return on Equity % | 12.54 | 15 |
| Return on Assets % | 4.56 | 7.35 |
|
Cash+ ST Inv. Per Share
|
12 | 1.25 |
| Total Debt | 98,542.4 | 33,425.0 |
| Total Debt to Equity % | 102.48 | 50.29 |
| Total Debt to Tangible Equity % | 102.48 | n/a |
|
Debt to Asset %
|
37.23 | 24.63 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
*Finance |
|
|
Real Estate |
|
|
|
Homebuilders and Manufactured Buildings
Companies engaged in the building and remodeling of residential properties. This category also includes manufactured buildings.
|
|
|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Scientific Products |
|
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
|
|
*Media |
|
|
|
Entertainment/Programming |
|
|
|
Television, Film and Video
Companies involved in the production, post-production, and distribution of Motion Pictures and Television programming.
|
|
|
|
Manufacturing |
|
|
|
Consumer Manufacturing |
|
|
|
Food, Beverage and Agriculture
Includes agricultural inputs like livestock and crops, as well as processed food and beverage products. Tobacco growers and cigarette manufacturers are also included.
|
|
|
|
Household Products
The Household Products sector includes furniture and other home and institutional decorative items, major and small appliances, kitchenware, and other related products.
|
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Industrial Manufacturing |
|
|
|
Transportation Equipment
Includes vehicles and other equipment designed for personal and commercial transportation activities. Jets, airplanes, and helicopters are excluded and can be found in the Aerospace and Defense hierarchy.
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Finance |
|
|
|
Real Estate |
|
|
Homebuilders and Manufactured Buildings |
|
|
Manufactured Buildings |
|
|
|
Manufactured Housing
Manufactured housing refers to homes and dwellings which are built off-site (usually in a factory), and trucked to the building lot where they are installed. Manufactured homes are generally designed based on pre-determined templates and built using highly standardized processes, allowing for significant cost savings.
Buyer Products:
|
|
|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
|
Upper Respiratory |
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Arrhythmia |
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Psoriasis |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, and causing the shedding of the horny layer of the skin by modulating cell differentiation and proliferation.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
Antisecretory Agents/Nitroimidazoles/Tetracyclines
Therapeutics that treat peptic ulcers by preventing the secretion of acid as well as treating infections by using antibiotics.
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Target Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Target Products:
|
|
|
|
Diarrhea |
|
|
|
Antisecretory Agents
Therapeutics that treat diarrhea by bringing fluid movement within the intestine to normal levels.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, and causing the shedding of the horny layer of the skin by modulating cell differentiation and proliferation.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Heliobacter pylori |
|
|
|
Antisecretory Agents/Nitroimidazoles/Tetracyclines
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Heterotopic Ossification |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat ossification by inhibiting the loss of bone material by osteoclasts.
Target Products:
|
|
|
|
Osteoporosis |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Target Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Target Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Calcium Channel Inhibitors
Therapeutics that treat spasticity by preventing the release of calcium from the sarcoplasmic reticulum which results in reduced involuntary muscle contractions.
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Female Genital Disorders |
|
|
|
Sexual Dysfunction |
|
|
|
Androgens
Therapeutics that treat female sexual dysfunction by providing male sex hormone, such as testosterone, that is important for the normal functioning of the female reproductive system.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Amphetamines
Therapeutics that treat coughs and colds by helping to relieve nasal congestion.
Target Products:
|
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Target Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Target Products:
|
|
|
|
Antitussives/Expectorants
Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.
Target Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Target Products:
|
|
|
|
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.
Target Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Target Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Target Products:
|
|
|
|
Expectorants/Opioids
Therapeutics that treat coughs and colds by suppressing the cough and helping in the ejection of the mucous.
Target Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Hyperthermia |
|
|
|
Calcium Channel Inhibitors
Therapeutics that treat hyperthermia by preventing the release of calcium from the sarcoplasmic reticulum which results in inhibits the catabolic processes responsible for increase in temperature.
Target Products:
|
|
|
|
Urology |
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies |
|
|
|
Diagnostic |
|
|
|
Temperature |
|
|
|
Thermometers
Medical instruments designed to measure the temperature in patients
Target Products:
|
|
|
|
Orthopedics |
|
|
|
Treatment |
|
|
|
Pain Management |
|
|
|
General Purpose |
|
|
|
Dry Heat Therapy
Devices that control the of use dry heat to ease pain associated with musculoskeletal injuries.
Target Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Consumables |
|
|
|
Bioanalytical Chemistry |
|
|
|
Cell Biology |
|
|
|
Cell Proliferation |
|
|
|
Kits
Cell proliferation consumables that are a collection of reagents, standards, and other consumables assembled for used in various biological analyses.
Target Products:
|
|
|
|
*Media |
|
|
|
Entertainment/Programming |
|
|
|
Television, Film and Video |
|
|
|
Production |
|
|
|
Television |
|
|
|
Domestic |
|
|
|
Soap Opera
Shows depicting the interconnected lives of many characters often in a sentimental, melodramatic way.
Target Products:
|
|
|
|
Manufacturing |
|
|
|
Consumer Manufacturing |
|
|
|
Food, Beverage and Agriculture |
|
|
|
Beverages |
|
|
|
Non-Alcoholic Beverages |
|
|
|
Coffee/Tea
Coffee and Tea Manufacturing.
Target Products:
|
|
|
|
Food |
|
|
|
Pet Food
Food for dogs and cats.
Target Products:
|
|
|
|
Sweets/Snacks |
|
|
|
Snack Foods
Manufacturers of Potato Chips, Peanuts, Trail Mix, and Cheese Snacks.
Target Products:
|
|
|
|
Household Products |
|
|
|
Household Appliances and Tools |
|
|
|
Other Household Products |
|
|
|
Brooms, Brushes, and Mops
Brooms, brushes, mops, and other manual cleaning equipment.
Target Products:
|
|
|
|
Small Electrical Appliances/Accessories |
|
|
|
Consumer Batteries
Relatively small, portable batteries used to power all varieties of consumer electronic devices. These one-time-use or rechargeable batteries store electric energy and can be used to power various devices ranging from CD players to cell phones. The most popular battery types include: lithium (Li), lithium ion (Li-ion), nickel-metal hybrid (NiMH), and nickel-cadmium (NiCAD). Flashlights are included at this level.
Target Products:
|
|
|
|
Kitchen/Bath Appliances
Electrical Kitchen/Bath Appliances, including toasters; juicemakers; and food blenders, as well as electrical toothbrushes, hairdryers, and electric massagers.
Target Products:
|
|
|
|
Personal Care and Cleaning Products |
|
|
|
Absorbent Products
Absorbent products, including tampons, pads, and diapers.
Target Products:
|
|
|
|
Anti-Perspirant
Anti-Perspirant and/or deodorant.
Target Products:
|
|
|
|
Cosmetics
Companies engaged in the manufacturing of cosmetics, such as lipstick, powders, and other make-up.
Target Products:
|
|
|
|
Fragrances
Companies engaged in the manufacturing of fragrances, such as perfume and cologne.
Target Products:
|
|
|
|
Hair Care
Companies engaged in the manufacturing of hair care products, such as shampoo, conditioner, hair dye, hair spray, styling gel, and mousse. Also includes hair accessories, such as pins, clips, and curlers.
Target Products:
|
|
|
|
Household Cleaning Products
Chemical-based household cleaning products, such as detergent and surface cleaner. Also includes automotive cleaning products.
Target Products:
|
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Target Products:
|
|
|
|
Sanitary/Personal Care Paper
Companies engaged in the manufacturing of sanitary/personal care paper such as napkins and tissues.
Target Products:
|
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Target Products:
|
|
|
|
Soap/Body Wash
Soap, Body Wash, and Shower Gel.
Target Products:
|
|
|
|
Industrial Manufacturing |
|
|
|
Transportation Equipment |
|
|
|
Commercial Transportation Equipment |
|
|
|
Heavy Duty Trucks and Trailers
Heavy duty cargo transportation trucks and trailers. Trailers may be specialized for dry freight, refrigerated storage, livestock, and other transport needs.
Buyer Products:
|
|
|
|
Consumer Vehicles |
|
|
|
Cars
Cars, light trucks, (including vans), and sports utility vehicles, designed primarily for transportation purposes on paved streets.
Buyer Products:
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
DaimlerChrysler AG (USA)
|
|
n/a | 92,369.355 | 14.08 | 18.69 | 0.46 | 0.48 | 2.21 | |
|
Volkswagen AG (ADR)
|
|
n/a | 65,126.547 | 15.48 | 14.37 | 0.46 | 0.44 | 2.39 | |
| Target | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 149,901.705 | 13.83 | 13.31 | 3.25 | 3.25 | 14.13 | |
|
PepsiCo, Inc.
|
|
n/a | 105,342.452 | 18.45 | 19.80 | 2.99 | 2.82 | 11.04 | |
|
Bayer AG (ADR)
|
|
n/a | 57,937.117 | 11.18 | 16.31 | 1.43 | 1.34 | n/a | |
|
Diageo plc (ADR)
|
|
n/a | 56,250.384 | 19.51 | 18.56 | 3.74 | 3.16 | n/a | |
|
Unilever plc (ADR)
|
|
n/a | 54,917.014 | 7.91 | 18.14 | 1.01 | 1.03 | n/a | |
|
Unilever N.V. (ADR)
|
|
n/a | 52,955.693 | 8.06 | 17.65 | 0.97 | 0.87 | n/a | |
|
Koninklijke Philips Electronics NV (ADR)
|
|
n/a | 47,270.498 | 4.66 | 21.63 | 1.29 | 1.30 | 2.17 | |
|
Cadbury Schweppes plc (ADR)
|
|
n/a | 27,491.781 | 11.81 | 24.52 | 1.86 | 1.97 | n/a | |
|
Covidien Ltd.
|
|
n/a | 20,975.938 | 14.64 | 15.63 | 2.11 | 2.12 | 15.94 | |
|
Avon Products, Inc.
|
|
n/a | 17,290.967 | 30.26 | 24.33 | 1.93 | 1.83 | 22.39 | |
|
Gucci Group N.V. (ADR)
|
|
n/a | 14,154.965 | 66.13 | n/a | 4.45 | n/a | 8.61 | |
|
The Estee Lauder Companies Inc.
|
|
n/a | 9,113.611 | 22.50 | 21.36 | 1.32 | 1.31 | 30.10 | |
|
Energizer Holdings, Inc.
|
|
n/a | 6,019.360 | 21.55 | 20.74 | 1.85 | 1.79 | n/a | |
|
International Flavors & Fragrances Inc.
|
|
n/a | 4,626.899 | 19.65 | 19.93 | 2.15 | n/a | 23.44 | |
|
Church & Dwight Co., Inc.
|
|
n/a | 3,201.353 | 22.22 | 20.83 | 1.59 | 1.51 | n/a | |
|
Kyphon Inc.
|
|
n/a | 2,506.280 | 289.98 | 47.50 | 5.64 | 4.24 | n/a | |
|
Del Monte Foods Company
|
|
n/a | 2,483.815 | 22.06 | 15.45 | 0.73 | 0.70 | n/a | |
|
Adams Respiratory Therapeutics, Inc.
|
|
n/a | 1,426.243 | 37.61 | 40.46 | 4.22 | 4.49 | 9.55 | |
|
Chattem Inc.
|
|
n/a | 1,176.888 | 24.17 | 20.71 | 3.35 | 2.77 | n/a | |
|
Playtex Products, Inc.
|
|
n/a | 1,158.177 | 34.45 | 35.19 | 1.81 | 1.54 | n/a | |
|
Delphi Corporation
|
|
n/a | 1,134.799 | n/a | -0.75 | 0.04 | 0.04 | n/a | |
|
Axcan Pharma Inc. (USA)
|
|
n/a | 901.452 | 15.85 | 16.95 | 2.88 | 2.85 | 7.79 | |
|
Helen of Troy Limited
|
|
n/a | 811.456 | 15.16 | 14.41 | 1.26 | 1.20 | 7.63 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Publicis Groupe S.A. (ADR)
|
|
n/a | 8,190.570 | 13.63 | 15.82 | 1.38 | 1.22 | n/a | |
|
Dassault Systemes S.A. (ADR)
|
|
n/a | 7,229.980 | 29.51 | 25.41 | 4.47 | 4.26 | 4.68 | |
|
BEA Systems, Inc.
|
|
n/a | 5,382.190 | 37.36 | 31.59 | 4.15 | 3.68 | 5.26 | |
|
Focus Media Holding Limited (ADR)
|
|
n/a | 4,828.274 | 53.61 | 34.83 | 20.26 | 12.23 | 12.96 | |
|
Business Objects S.A. (ADR)
|
|
n/a | 4,082.666 | 59.51 | 25.32 | 3.12 | 2.73 | 9.17 | |
|
Fair Isaac Corporation
|
|
n/a | 2,231.363 | 22.15 | 24.36 | 2.71 | 2.82 | n/a | |
|
Progress Software Corporation
|
|
n/a | 1,307.102 | 39.73 | 22.88 | 2.79 | 2.73 | 5.29 | |
|
Littelfuse, Inc.
|
|
n/a | 784.259 | 37.93 | 20.53 | 1.45 | 1.48 | 3.53 | |
|
CECO Environmental Corp.
|
|
n/a | 146.505 | 29.45 | 31.80 | 0.95 | 0.69 | n/a | |
|
Datawatch Corporation
|
|
n/a | 32.557 | n/a | 30.84 | 1.44 | 1.35 | n/a | |
|
Insightful Corporation
|
|
n/a | 29.267 | n/a | n/a | 1.19 | n/a | 2.96 | |
| Buyer | |||||||||
|
NetSol Technologies Inc.
|
|
12.00% | 30.270 | n/a | n/a | 1.19 | n/a | 2.09 | |
|
Gentex Corporation
|
|
10.00% | 2,991.252 | 26.74 | 25.25 | 5.07 | 4.71 | 4.19 | |
| Target | |||||||||
|
Nastech Pharmaceutical Co. Inc.
|
|
77.00% | 321.300 | n/a | -8.01 | 12.01 | 12.60 | 4.32 | |
|
Alexion Pharmaceuticals, Inc.
|
|
37.70% | 1,839.069 | n/a | -13.35 | 258.75 | 47.08 | 20.67 | |
|
Multi-Color Corp.
|
|
30.00% | 280.777 | 25.46 | n/a | 1.26 | n/a | 5.50 | |
|
Tredegar Corporation
|
|
23.40% | 836.845 | 20.75 | 18.31 | 0.74 | n/a | 2.13 | |
|
Griffon Corporation
|
|
14.00% | 620.345 | 13.33 | 18.46 | 0.36 | n/a | 1.92 | |
|
Buckeye Technologies Inc.
|
|
13.00% | 585.159 | 37.97 | 29.88 | 0.77 | 0.88 | 3.65 | |
|
Sonoco Products Company
|
|
12.00% | 3,800.129 | 18.72 | 18.26 | 1.00 | 1.11 | 10.47 | |
|
Publicis Groupe S.A. (ADR)
|
|
10.00% | 8,190.570 | 13.63 | 15.82 | 1.38 | 1.22 | n/a | |
|
Valassis Communications, Inc.
|
|
10.00% | 730.645 | 16.43 | 12.26 | 0.63 | 0.32 | n/a | |
|
Curis, Inc.
|
|
5.00% | 63.208 | n/a | -5.25 | 4.14 | 4.44 | 2.60 | |
|
American Express Company
|
|
n/a | 76,677.562 | 19.71 | 18.75 | 2.70 | 2.64 | 7.31 | |
|
WPP Group plc (ADR)
|
|
n/a | 18,437.984 | 20.61 | 17.38 | 1.52 | 1.52 | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 24,837.216 | 16.04 | 18.15 | 1.35 | 1.68 | 5.34 | |
|
CarMax, Inc
|
|
n/a | 5,482.535 | 26.46 | 23.63 | 0.71 | 0.64 | 4.13 | |
|
AutoNation, Inc.
|
|
n/a | 4,490.653 | 14.61 | 13.46 | 0.24 | 0.24 | 6.18 | |
|
Penske Automotive Group, Inc.
|
|
n/a | 1,987.742 | 17.24 | 14.37 | 0.17 | 0.16 | n/a | |
|
Sonic Automotive, Inc.
|
|
n/a | 1,245.460 | 14.82 | 11.33 | 0.15 | 0.15 | n/a | |
|
Brilliance China Automotive Hldg. (ADR)
|
|
n/a | 1,040.723 | n/a | 23.33 | 0.76 | 0.71 | 1.58 | |
|
Group 1 Automotive, Inc.
|
|
n/a | 927.960 | 11.11 | 9.93 | 0.15 | 0.14 | n/a | |
|
Asbury Automotive Group, Inc.
|
|
n/a | 765.956 | 15.75 | 10.62 | 0.13 | 0.13 | 6.26 | |
|
Lithia Motors, Inc.
|
|
n/a | 471.253 | 13.46 | 12.15 | 0.15 | 0.14 | 4.25 | |
| Target | |||||||||
|
Wal-Mart Stores, Inc.
|
|
15.00% | 197,467.881 | 17.18 | 15.25 | 0.56 | 0.52 | 4.36 | |
|
sanofi-aventis (ADR)
|
|
n/a | 117,047.304 | 21.40 | 11.89 | 2.91 | 2.99 | n/a | |
|
Sally Beauty Holdings, Inc.
|
|
n/a | 1,613.882 | 27.17 | 28.53 | 0.66 | 0.66 | n/a | |
|
99 Cents Only Stores
|
|
n/a | 945.448 | 96.84 | 48.34 | 0.86 | 0.80 | 1.82 | |
|
Helen of Troy Limited
|
|
n/a | 811.456 | 15.16 | 14.41 | 1.26 | 1.20 | 7.63 | |
|
Prestige Brands Holdings, Inc.
|
|
n/a | 675.571 | 18.72 | 18.36 | 2.12 | 2.02 | n/a | |
|
Fred's, Inc.
|
|
n/a | 526.283 | 19.58 | 17.45 | 0.29 | 0.29 | 1.41 | |
|
United-Guardian, Inc.
|
|
n/a | 70.135 | 21.42 | n/a | 5.17 | n/a | 4.87 | |
|
AMCON Distributing Co.
|
|
n/a | 14.681 | 14.32 | n/a | 0.02 | n/a | n/a | |
|
Synergy Brands, Inc.
|
|
n/a | 7.612 | n/a | n/a | 0.10 | n/a | 1.30 | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Exxon Mobil Corporation
|
|
n/a | 517,922.849 | 12.83 | 12.98 | 1.38 | 1.39 | 4.54 | |
|
Microsoft Corporation
|
|
n/a | 298,101.768 | 21.51 | 21.18 | 6.02 | 5.81 | 11.48 | |
| Target | |||||||||
|
Wal-Mart Stores, Inc.
|
|
n/a | 197,467.881 | 17.18 | 15.25 | 0.56 | 0.52 | 4.36 | |
|
Berkshire Hathaway Inc.
|
|
n/a | 170,040.803 | 15.05 | n/a | 1.56 | n/a | 2.20 | |
|
sanofi-aventis (ADR)
|
|
n/a | 117,047.304 | 21.40 | 11.89 | 2.91 | 2.99 | n/a | |
|
The Clorox Company
|
|
n/a | 9,697.509 | 20.25 | 19.18 | 2.01 | 1.94 | n/a | |
|
Electrolux AB (ADR)
|
|
n/a | 7,862.024 | 17.94 | n/a | 0.50 | n/a | 5.18 | |
|
Invitrogen Corporation
|
|
n/a | 3,505.434 | n/a | 21.88 | 2.78 | 2.93 | n/a | |
|
Wesco Financial Corporation
|
|
n/a | 2,795.309 | 30.65 | n/a | 4.64 | n/a | 1.31 | |
|
Inverness Medical Innovations, Inc.
|
|
n/a | 2,325.981 | n/a | 43.02 | 3.87 | 3.01 | 8.43 | |
|
Alexion Pharmaceuticals, Inc.
|
|
n/a | 1,839.069 | n/a | -13.35 | 258.75 | 47.08 | 20.67 | |
|
Regis Corporation
|
|
n/a | 1,630.375 | 16.84 | 17.12 | 0.63 | 0.62 | n/a | |
|
Sally Beauty Holdings, Inc.
|
|
n/a | 1,613.882 | 27.17 | 28.53 | 0.66 | 0.66 | n/a | |
|
Arbitron Inc.
|
|
n/a | 1,571.384 | 32.76 | 37.28 | 4.68 | 4.61 | 23.96 | |
|
Macrovision Corporation
|
|
n/a | 1,318.406 | 36.34 | 24.28 | 5.15 | 4.72 | 4.30 | |
|
NACCO Industries, Inc.
|
|
n/a | 1,239.222 | 12.38 | n/a | 0.37 | n/a | 4.43 | |
|
Regeneron Pharmaceuticals, Inc.
|
|
n/a | 1,131.859 | n/a | -9.56 | 18.55 | 14.57 | 5.75 | |
|
99 Cents Only Stores
|
|
n/a | 945.448 | 96.84 | 48.34 | 0.86 | 0.80 | 1.82 | |
|
Helen of Troy Limited
|
|
n/a | 811.456 | 15.16 | 14.41 | 1.26 | 1.20 | 7.63 | |
|
Palomar Medical Technologies, Inc.
|
|
n/a | 704.169 | 13.39 | 29.63 | 5.19 | 5.11 | 5.63 | |
|
Syneron Medical Ltd.
|
|
n/a | 678.436 | 17.23 | 15.17 | 5.40 | 4.87 | 3.25 | |
|
Prestige Brands Holdings, Inc.
|
|
n/a | 675.571 | 18.72 | 18.36 | 2.12 | 2.02 | n/a | |
|
Shutterfly, Inc.
|
|
n/a | 586.972 | 93.11 | 68.74 | 4.41 | 3.43 | 3.91 | |
|
Fred's, Inc.
|
|
n/a | 526.283 | 19.58 | 17.45 | 0.29 | 0.29 | 1.41 | |
|
Noven Pharmaceuticals, Inc.
|
|
n/a | 496.009 | 24.17 | 20.53 | 7.11 | 5.69 | 2.73 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 194,565.5 | 75,046.0 | 269,611.5 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 194,565.5 | 75,046.0 | 269,611.5 |
|
Cost of Revenue
|
156,220.4 | 36,103.0 | 192,323.4 |
|
SG&A Expense
|
20,156.9 | 23,944.0 | 44,100.9 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
| Total Expenses | 176,377.4 | 60,047.0 | 236,424.4 |
|
Operating Income
|
18,188.1 | 14,999.0 | 33,187.1 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
939.3 | -1,276.0 | -336.7 |
|
Other, Net
|
229.2 | 490.0 | 719.2 |
| Income Before Taxes | 19,356.7 | 14,213.0 | 33,569.7 |
| Income Taxes | 7,298.3 | 4,243.0 | 11,541.3 |
| Income After Taxes | 12,058.4 | 9,970.0 | 22,028.4 |
| Minority Interest (IS) | -403.7 | 0.0 | -403.7 |
| Equity in Affiliates | 1,702.2 | 0.0 | 1,702.2 |
|
Net Income - Excl. Xord. Items
|
13,356.9 | 9,970.0 | 23,326.9 |
|
Net Income - Incl. Xord. Items
|
13,356.9 | 9,970.0 | 23,326.9 |
| Preferred Dividends | 0.0 | -157.0 | -157.0 |
|
Income Avail. to Common
|
13,356.9 | 9,813.0 | 23,169.9 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
1,598.9 | 3,397.3 | 4,996.2 |
|
Basic EPS - Excl. Xord. Items
|
8.35 | 2.89 | 4.67 |
|
Basic EPS - Incl. Xord. Items
|
8.35 | 2.89 | 4.67 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 1,600.1 | 3,397.3 | 4,997.4 |
|
F.D. EPS - Excl. Xord. Items
|
8.35 | 2.89 | 4.67 |
|
F.D. EPS - Incl. Xord. Items
|
8.35 | 2.89 | 4.67 |
| Dividends Per Common Share | 1.95 | 1.24 | 3.19 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
15,439.6 | 3,994.0 | 19,433.6 |
|
ST Investments
|
3,754.9 | 236.0 | 3,990.9 |
|
Accounts Receivable
|
53,185.6 | 6,757.0 | 59,942.6 |
|
Inventory
|
14,656.2 | 7,091.0 | 21,747.2 |
|
Prepayments and Advances
|
4,222.8 | 2,938.0 | 7,160.8 |
|
Other Current Assets
|
4,480.7 | 1,698.0 | 6,178.7 |
|
Current Assets
|
95,739.7 | 22,714.0 | 118,453.7 |
|
PPE
|
142,352.5 | 34,132.0 | 176,484.5 |
|
Accum D&A
|
-76,865.1 | -14,954.0 | -91,819.1 |
|
PPE, Net
|
65,487.4 | 19,178.0 | 84,665.4 |
| Goodwill & Intangibles | 0.0 | 89,934.0 | 89,934.0 |
| Long Term Investments | 47,837.1 | 0.0 | 47,837.1 |
|
Note Receivable
|
47,052.6 | 0.0 | 47,052.6 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
8,535.8 | 3,869.0 | 12,404.8 |
| Total Assets | 264,652.7 | 135,695.0 | 400,347.7 |
| Liabilities | |||
| Accounts Payable | 17,968.0 | 4,371.0 | 22,339.0 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 13,554.3 | 10,777.0 | 24,331.3 |
|
ST Debt
|
28,414.4 | 0.0 | 28,414.4 |
|
Curr Port of LTD & Cap Lease Oblg
|
19,239.7 | 12,168.0 | 31,407.7 |
| Other (Current) Liabilities | 16,425.6 | 3,605.0 | 20,030.6 |
|
Current Liab.
|
95,602.0 | 30,921.0 | 126,523.0 |
|
LT Debt
|
50,888.3 | 21,257.0 | 72,145.3 |
|
Total LT Debt
|
50,888.3 | 21,257.0 | 72,145.3 |
| Minority Interest (BS) | 5,104.1 | 0.0 | 5,104.1 |
| Deferred Taxes | 10,662.6 | 12,272.0 | 22,934.6 |
|
Other LT Liab.
|
6,233.8 | 4,779.0 | 11,012.8 |
|
Total Liabilities
|
168,490.8 | 69,229.0 | 237,719.8 |
| Shareholders Equity | |||
| Redeemable Preferred | 0.0 | 1,413.0 | 1,413.0 |
| Common Stock | 3,225.8 | 3,987.0 | 7,212.8 |
| Additional Paid in Capital | 4,042.7 | 58,912.0 | 62,954.7 |
| Retained Earnings | 95,582.0 | 40,477.0 | 136,059.0 |
| Treasure Stock | -12,387.0 | -37,405.0 | -49,792.0 |
| Other Equity | 5,698.4 | 386.0 | 6,084.4 |
| ESOP Debt Guarantee | 0.0 | -1,304.0 | -1,304.0 |
|
Total Equity
|
96,161.9 | 66,466.0 | 162,627.9 |
|
Total Liab. & Equity
|
264,652.7 | 135,695.0 | 400,347.7 |
|
Shares Outstanding
|
1,599.0 | 3,148.9 | 4,747.9 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 13,356.9 | 9,970.0 | 23,326.9 |
| CF Depreciation | 11,232.8 | 3,103.0 | 14,335.8 |
| CF Deferred Taxes | 1,074.9 | 78.0 | 1,152.9 |
| Other Non-Cash Items | -527.6 | 575.0 | 47.4 |
| Change in Working Capital | 1,171.3 | -683.0 | 488.3 |
| Total Cash From Operating Activities | 26,308.4 | 13,043.0 | 39,351.4 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -23,039.5 | -2,997.0 | -26,036.5 |
| Other Investing Cash Flows | -7,950.3 | 1,693.0 | -6,257.3 |
| Total Cash From Investing Activities | -30,989.8 | -1,304.0 | -32,293.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -2,755.1 | -4,127.0 | -6,882.1 |
| Purchase Or Sale of Stock | -2,402.4 | -8,882.0 | -11,284.4 |
| Purchase and Retirement of Debt | 12,321.4 | -3,735.0 | 8,586.4 |
| Other Financing Cash Flow | 0.0 | 0.0 | 0.0 |
| Total Cash From Financing Activities | 7,163.9 | -16,744.0 | -9,580.1 |
| Exchange Rate Effects | 206.6 | 324.0 | 530.6 |
| Net Change in Cash | 2,689.1 | -4,681.0 | -1,991.9 |
| Cash Taxes Paid | 6,026.7 | 2,869.0 | 8,895.7 |
| Cash Interest Paid | 4,471.7 | 1,045.0 | 5,516.7 |